HEM Pharma Inc. Logo

HEM Pharma Inc.

Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.

376270 | KO

Overview

Corporate Details

ISIN(s):
KR7376270005
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 711호, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HEM Pharma Inc. is a biotechnology company specializing in human microbiome research and technology. The company develops personalized healthcare solutions, probiotics, health functional foods, and Live Biotherapeutic Products (LBPs). Its core competency lies in its proprietary Personalized Microbiome Analysis System (PMAS), a screening platform used to identify and develop customized microbial solutions based on multi-omics and metabolome analysis. HEM Pharma also utilizes its MBR high-concentration fermentation technology for efficient production and offers Contract Development and Manufacturing Organization (CDMO) services through its GMP-certified facilities, supporting the entire lifecycle of microbiome-based products from research to manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-21 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.4 MB
2025-05-08 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 4.9 KB
2025-04-23 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 62.3 KB
2025-04-03 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.5 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.2 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.3 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.2 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.0 KB
2025-03-31 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB

Automate Your Workflow. Get a real-time feed of all HEM Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEM Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEM Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.